

# Help more patients get the cancer testing they need to **better manage their health**

Medically underserved patients are screened for cancer less often. Quest can help change that.



## At higher risk but with lower rates of cancer screening and testing

People living in **low- and middle-income areas** in the United States are at **higher risk of dying from cancer** than are those who live in high-income areas.<sup>1</sup> Yet low-income and other medically underserved populations experience lower rates of cancer screening.<sup>7</sup>



< **45%**

of FQHC patients in FQHCs  
are screened for colorectal  
cancer (CRC)<sup>2</sup>



**BRCA**

**genetic breast cancer testing**  
is underutilized in women from  
underserved populations<sup>3-5</sup>

## Quest can help you close the gaps

Quest offers cancer screening, testing, and services for greater access to testing and improved adherence rates. Our offering includes:

- An end-to-end **at-home CRC screening program** with cost-effective testing
- **Genetic testing** to assess risk of breast, colon, uterine, and other cancers
- **Broad health plan** coverage and financial assistance program
- **Professional consultation** with geneticists and genetic counselors

**Cancer testing and services from Quest can help you improve screening rates and make sure your patients are getting the vital testing they need.**

**People with Lynch  
syndrome** have up to an

**80%**

lifetime risk for CRC<sup>6</sup>

# With Quest, your patients can easily access **innovative cancer testing**

## InSure® ONE™ CRC Program

InSure® ONE™ is a convenient, at-home, self-collection fecal immunochemical test (FIT) that qualitatively detects human hemoglobin from blood in stool samples.

- The only FIT test that is performed using toilet water collected from a single bowel movement
- No stool collection or handling required, no dietary or medicinal restrictions—which helps increase the likelihood your patient will complete the test
- Includes patient reminders and FQHC quality measures reporting



In a 2019 study, FIT tests such as InSure® ONE™ were found to be **more effective and considerably less costly** than DNA stool testing.<sup>8</sup>

## Lynch Syndrome Panel

Tests for 5 high-risk genes (*MLH1*, *MSH2*, *MSH6*, *PMS2*, and *EPCAM*) predominantly associated with colon, endometrial, ovarian, and gastric cancers.

- Targeted testing is available for those who have previously tested positive for Lynch syndrome or have a relative who previously tested positive
- Patient education materials available

## Hereditary Breast Cancer Testing

A comprehensive, medically responsible portfolio of clinically relevant tests designed to align with professional society guidelines.

- Flexible test options for focused or comprehensive risk testing
- More than 30 years of experience in genetic testing



### Broad health plan coverage for patient access

Quest has access to approximately 90% of US insured lives.



### Financial assistance program to help your patients in need

We offer assistance for uninsured and underinsured patients who meet or fall below the federal poverty level.



### Genetics expertise available for consult

Consult with one of our board-certified medical geneticists or lab-based genetic counselors when you have a question about a test, a result, or patient eligibility.

**1.866.GENE.INFO (1.866.436.3463)**



## Close the gaps in cancer testing

Quest provides innovative technologies in screening and detection so you can offer your patients a comprehensive range of user-friendly testing options. Ask your Quest representative for details.

## References

1. JAMA Netw Open. 2018;1(6):e183146. doi:10.1001/jamanetworkopen.2018.3146 2. National Colorectal Cancer Roundtable. CRC screening rates reach 44.4% in FQHCs in 2018. <https://nccrt.org/colorectal-cancer-screening-rates-reach-44-1-in-fqhcs-in-2018/> Accessed July 13, 2020. 3. Cragun D, Bonner D, Kim J, Akbar Mi, Narod S, Gomez-Fuego A, et al. Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancer. *Breast Cancer Res Treat.* 2015;151:169–176. 4. Pal T, Bonner D, Cragun D, Monteiro A, Phelan C, Servais L, et al. A high frequency of BRCA mutations in young black women with breast cancer residing in Florida. *Cancer.* 2015;121:4173–4180. 5. Olaya W, Esquivel P, Wong J, Morgan J, Freeberg A, Roy-Chowdhury S, et al. Disparities in BRCA testing: when insurance coverage is not a barrier. *Am J Surg.* 2009;198:562–565. 6. Cancer.Net (American Society of Clinical Oncology). Lynch syndrome. <https://www.cancer.net/cancer-types/lynch-syndrome#:~:text=Lynch%20syndrome%2C%20also%20known%20as,of%20certain%20types%20of%20cancer>. Accessed July 13, 2020 7. Javiera Martinez-Gutierrez J, Jhingan E, Angulo A, et al. Cancer screening at a federally qualified health center: a qualitative study on organizational challenges in the era of health care reform. *J Immigr Minor Health.* 2013;15(5): 993–1000. 8. Naber SK, Knudsen AB, Zauber AG, et al. Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. *PLoS ONE.* 2019;14(9):0220234. <https://doi.org/10.1371/journal.pone.0220234>

## QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. ©2020 Quest Diagnostics Incorporated. All rights reserved. SB9312 10/2020

